Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$152 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.7
Industry P/E
--
EV/EBITDA
-2.3
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$3
EPS
$-1.9
Face value
--
Shares outstanding
70,931,016
CFO
$-675.89 Mln
EBITDA
$-944.29 Mln
Net Profit
$-863.28 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
| 98.5 | 12.1 | 98.5 | 92.8 | -46.2 | -42.7 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
| -55.4 | -79.7 | -24.8 | -76.0 | 61.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
2.7 | 151.8 | 0.0 | -137.1 | -- | -49.5 | -- | 0.7 |
| 61.5 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.1 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.7 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.0 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.2 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.3 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 495.4 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 312.0 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a... Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Address: 10275 Science Center Dr., San Diego, CA, United States, 92121 Read more
CEO & Director
Dr. Kimberly Lynn Blackwell M.D.
CEO & Director
Dr. Kimberly Lynn Blackwell M.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Zentalis Pharmaceuticals Inc (ZNTL) is $2.68 (NASDAQ) as of 02-Apr-2026 12:34 EDT. Zentalis Pharmaceuticals Inc (ZNTL) has given a return of -46.19% in the last 3 years.
Since, TTM earnings of Zentalis Pharmaceuticals Inc (ZNTL) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.71
|
0.45
|
|
2024
|
-1.30
|
0.64
|
|
2023
|
-3.37
|
2.25
|
|
2022
|
-4.51
|
2.46
|
|
2021
|
-22.77
|
9.93
|
The 52-week high and low of Zentalis Pharmaceuticals Inc (ZNTL) are Rs 3.95 and Rs 1.01 as of 02-Apr-2026.
Zentalis Pharmaceuticals Inc (ZNTL) has a market capitalisation of $ 152 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Zentalis Pharmaceuticals Inc (ZNTL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.